marketcaparena
Search

    DHR

    DANAHER CORP /DE/

    Company overview

    Market capitalization
    $159.81B
    Employees
    58,000
    Latest publication
    2026-09-29
    About DANAHER CORP /DE/

    Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-26 · USDQ1 20262026-03-27 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue6,265,000,000USD5,951,000,000USD6,838,000,000USD6,053,000,000USD5,936,000,000USD5,741,000,000USD6,538,000,000USD5,798,000,000USD
    Cost Of Revenue2,654,000,000USD2,360,000,000USD2,872,000,000USD2,530,000,000USD1,981,000,000USD2,215,000,000USD2,648,000,000USD2,397,000,000USD
    Gross Profit3,611,000,000USD3,591,000,000USD3,966,000,000USD3,523,000,000USD3,955,000,000USD3,526,000,000USD3,890,000,000USD3,401,000,000USD
    Research Development412,000,000USD387,000,000USD438,000,000USD378,000,000USD403,000,000USD379,000,000USD442,000,000USD383,000,000USD
    Selling General Administrative2,072,000,000USD1,860,000,000USD2,026,000,000USD1,991,000,000USD2,360,000,000USD1,858,000,000USD2,023,000,000USD2,060,000,000USD
    Total Operating Expenses2,484,000,000USD2,247,000,000USD2,464,000,000USD2,369,000,000USD2,763,000,000USD2,237,000,000USD2,144,000,000USD2,443,000,000USD
    Operating Income1,127,000,000USD1,344,000,000USD1,502,000,000USD1,154,000,000USD1,192,000,000USD1,289,000,000USD1,746,000,000USD958,000,000USD
    Total Other Income Expense Net-49,000,000USD-109,000,000USD-129,000,000USD-78,000,000USD-537,000,000USD-160,000,000USD-431,000,000USD19,000,000USD
    Interest Income61,000,000USD27,000,000USD42,000,000USD3,000,000USD8,000,000USD6,000,000USD14,000,000USD4,000,000USD
    Interest Expense107,000,000USD63,000,000USD55,000,000USD67,000,000USD71,000,000USD72,000,000USD61,000,000USD87,000,000USD
    Income Before Tax1,078,000,000USD1,235,000,000USD1,373,000,000USD1,076,000,000USD655,000,000USD1,129,000,000USD1,315,000,000USD977,000,000USD
    Income Tax Expense208,000,000USD206,000,000USD176,000,000USD168,000,000USD100,000,000USD175,000,000USD229,000,000USD159,000,000USD
    Net Income870,000,000USD1,029,000,000USD1,197,000,000USD908,000,000USD555,000,000USD954,000,000USD1,086,000,000USD818,000,000USD
    Net Interest Income——-42,000,000USD-64,000,000USD-63,000,000USD-66,000,000USD-47,000,000USD-83,000,000USD
    Tax Provision——190,000,000USD168,000,000USD100,000,000USD175,000,000USD229,000,000USD159,000,000USD
    Net Income From Continuing Ops——1,183,000,000USD908,000,000USD555,000,000USD954,000,000USD1,086,000,000USD818,000,000USD
    Ebit——1,428,000,000USD1,143,000,000USD726,000,000USD1,201,000,000USD1,376,000,000USD1,064,000,000USD
    Ebitda——2,051,000,000USD1,765,000,000USD1,337,000,000USD1,792,000,000USD1,971,000,000USD1,655,000,000USD
    Depreciation And Amortization——623,000,000USD622,000,000USD611,000,000USD591,000,000USD595,000,000USD591,000,000USD
    Reconciled Depreciation——623,000,000USD622,000,000USD611,000,000USD591,000,000USD595,000,000USD591,000,000USD
    Net Income Applicable To Common Shares——1,197,000,000USD908,000,000USD555,000,000USD954,000,000USD1,086,000,000USD818,000,000USD
    Unclassified Operating Expenses——————-321,000,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-26 · USD
    Total Revenue12,216,000,000USD
    Cost Of Revenue5,014,000,000USD
    Gross Profit7,202,000,000USD
    Research Development799,000,000USD
    Selling General Administrative3,932,000,000USD
    Total Operating Expenses4,731,000,000USD
    Operating Income2,471,000,000USD
    Total Other Income Expense Net-158,000,000USD
    Interest Income88,000,000USD
    Interest Expense170,000,000USD
    Income Before Tax2,313,000,000USD
    Income Tax Expense414,000,000USD
    Net Income1,899,000,000USD
    SourceDisclosureDeterministicFinal

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20212021-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20132013-12-31 · USD
    Total Revenue24,568,000,000USD23,875,000,000USD23,890,000,000USD29,453,000,000USD17,048,500,000USD18,329,700,000USD16,882,400,000USD19,118,000,000USD
    Cost Of Revenue10,045,000,000USD9,669,000,000USD12,216,000,000USD11,501,000,000USD7,543,200,000USD8,099,200,000USD7,499,400,000USD9,133,900,000USD
    Gross Profit14,523,000,000USD14,206,000,000USD14,034,000,000USD17,952,000,000USD9,505,300,000USD10,230,500,000USD9,383,000,000USD9,984,100,000USD
    Research Development1,598,000,000USD1,584,000,000USD1,503,000,000USD1,742,000,000USD1,059,200,000USD1,128,800,000USD975,100,000USD1,249,900,000USD
    Selling General Administrative8,235,000,000USD7,759,000,000USD8,676,000,000USD8,198,000,000USD6,472,100,000USD6,042,500,000USD5,608,600,000USD5,432,800,000USD
    Total Operating Expenses9,833,000,000USD9,022,000,000USD8,832,000,000USD9,902,000,000USD6,435,200,000USD7,081,000,000USD6,395,700,000USD6,616,200,000USD
    Operating Income4,690,000,000USD5,184,000,000USD5,202,000,000USD8,050,000,000USD3,070,100,000USD3,149,500,000USD2,987,300,000USD3,367,900,000USD
    Total Other Income Expense Net-457,000,000USD-538,000,000USD-158,000,000USD-452,000,000USD-108,200,000USD-210,700,000USD-376,000,000USD198,100,000USD
    Interest Income30,000,000USD117,000,000USD215,000,000USD227,000,000USD9,200,000USD7,500,000USD200,000USD—
    Interest Expense265,000,000USD278,000,000USD286,000,000USD241,000,000USD136,900,000USD162,700,000USD184,400,000USD145,900,000USD
    Income Before Tax4,233,000,000USD4,646,000,000USD5,044,000,000USD7,598,000,000USD2,961,900,000USD2,938,800,000USD2,611,300,000USD3,566,000,000USD
    Income Tax Expense633,000,000USD747,000,000USD301,000,000USD1,251,000,000USD555,600,000USD469,000,000USD457,900,000USD871,000,000USD
    Discontinued Operations14,000,000USD——86,000,000USD244,600,000USD22,300,000USD400,300,000USD—
    Net Income3,614,000,000USD3,899,000,000USD4,743,000,000USD6,433,000,000USD2,650,900,000USD2,492,100,000USD2,553,700,000USD2,695,000,000USD
    Net Income Applicable To Common Shares3,614,000,000USD3,899,000,000USD4,743,000,000USD6,269,000,000USD2,650,900,000USD2,492,100,000USD2,553,700,000USD2,695,000,000USD
    Unclassified Operating Expenses—-321,000,000USD-1,347,000,000USD—-1,096,100,000USD-90,300,000USD-188,000,000USD-66,500,000USD
    Net Interest Income—-161,000,000USD-57,000,000USD-227,000,000USD-148,200,000USD-155,200,000USD-184,200,000USD—
    Tax Provision—747,000,000USD863,000,000USD1,251,000,000USD641,900,000USD469,000,000USD457,900,000USD—
    Net Income From Continuing Ops—3,899,000,000USD5,917,000,000USD6,347,000,000USD2,650,900,000USD2,469,800,000USD2,153,400,000USD2,695,000,000USD
    Ebit—4,924,000,000USD5,202,000,000USD7,839,000,000USD3,098,800,000USD3,101,500,000USD2,795,700,000USD3,711,900,000USD
    Ebitda—7,276,000,000USD5,202,000,000USD10,007,000,000USD4,276,500,000USD4,339,800,000USD3,923,800,000USD4,606,900,000USD
    Depreciation And Amortization—2,352,000,000USD2,166,000,000USD2,168,000,000USD1,177,700,000USD1,238,300,000USD1,128,100,000USD895,000,000USD
    Reconciled Depreciation—2,352,000,000USD2,238,000,000USD2,168,000,000USD1,307,700,000USD1,238,300,000USD——
    Non Operating Income Net Other———371,000,000USD46,400,000USD80,300,000USD44,800,000USD235,500,000USD
    Minority Interest————12,300,000USD9,600,000USD74,000,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-26 · USDQ1 20262026-03-27 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets92,367,000,000USD83,544,000,000USD83,464,000,000USD79,897,000,000USD81,620,000,000USD79,116,000,000USD77,542,000,000USD80,615,000,000USD
    Cash And Equivalents4,348,000,000USD5,701,000,000USD—1,528,000,000USD2,957,000,000USD1,993,000,000USD2,078,000,000USD2,627,000,000USD
    Total Current Assets13,381,000,000USD13,935,000,000USD12,756,000,000USD9,606,000,000USD10,999,000,000USD9,525,000,000USD9,497,000,000USD10,060,000,000USD
    Other Current Assets1,808,000,000USD1,807,000,000USD1,739,000,000USD1,649,000,000USD837,000,000USD686,000,000USD699,000,000USD1,248,000,000USD
    Other Non Current Assets4,389,000,000USD4,210,000,000USD4,209,000,000USD—————
    Total Liabilities39,775,000,000USD30,587,000,000USD30,923,000,000USD—————
    Total Current Liabilities8,105,000,000USD7,460,000,000USD6,807,000,000USD6,324,000,000USD6,792,000,000USD6,645,000,000USD6,798,000,000USD7,339,000,000USD
    Other Current Liabilities4,872,000,000USD4,747,000,000USD4,961,000,000USD—————
    Other Non Current Liabilities6,523,000,000USD5,566,000,000USD5,700,000,000USD—————
    Total Stockholder Equity52,581,000,000USD52,949,000,000USD52,534,000,000USD51,071,000,000USD52,334,000,000USD50,849,000,000USD49,543,000,000USD51,299,000,000USD
    Total Equity Including Noncontrolling Interest52,592,000,000USD52,957,000,000USD52,541,000,000USD—————
    Long Term Debt25,147,000,000USD17,561,000,000USD18,416,000,000USD16,833,000,000USD16,853,000,000USD15,976,000,000USD15,500,000,000USD16,324,000,000USD
    Net Receivables3,965,000,000USD3,819,000,000USD3,913,000,000USD3,755,000,000USD4,516,000,000USD4,314,000,000USD4,390,000,000USD3,507,000,000USD
    Inventory3,260,000,000USD2,608,000,000USD2,489,000,000USD2,674,000,000USD2,689,000,000USD2,532,000,000USD2,330,000,000USD2,678,000,000USD
    Property Plant Equipment Net5,825,000,000USD6,668,000,000USD6,745,000,000USD5,376,000,000USD6,409,000,000USD6,210,000,000USD6,074,000,000USD6,043,000,000USD
    Goodwill47,414,000,000USD42,765,000,000USD43,151,000,000USD—————
    Intangible Assets21,358,000,000USD17,166,000,000USD17,817,000,000USD18,097,000,000USD18,629,000,000USD18,885,000,000USD18,568,000,000USD19,854,000,000USD
    Accounts Payable1,822,000,000USD1,790,000,000USD1,844,000,000USD1,698,000,000USD1,725,000,000USD1,722,000,000USD1,753,000,000USD1,596,000,000USD
    Short Term Debt1,411,000,000USD923,000,000USD2,000,000USD23,000,000USD1,702,000,000USD1,601,000,000USD678,000,000USD2,500,000,000USD
    Common Stock9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD
    Retained Earnings48,226,000,000USD47,637,000,000USD46,891,000,000USD45,920,000,000USD45,239,000,000USD44,913,000,000USD44,188,000,000USD43,296,000,000USD
    Accumulated Other Comprehensive Income-795,000,000USD-593,000,000USD-207,000,000USD-590,000,000USD-569,000,000USD-1,612,000,000USD-3,218,000,000USD-1,310,000,000USD
    Deferred Revenue——1,353,000,000USD—————
    Deferred Revenue Non Current——231,000,000USD—————
    Total Liab———28,826,000,000USD29,278,000,000USD28,259,000,000USD27,992,000,000USD29,310,000,000USD
    Other Current Liab———4,603,000,000USD3,365,000,000USD3,322,000,000USD3,068,000,000USD3,243,000,000USD
    Capital Stock———9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD
    Good Will———42,948,000,000USD42,991,000,000USD41,657,000,000USD40,497,000,000USD42,173,000,000USD
    Other Assets———2,670,000,000USD2,592,000,000USD2,839,000,000USD2,906,000,000USD2,485,000,000USD
    Cash———1,528,000,000USD2,957,000,000USD1,993,000,000USD2,078,000,000USD2,627,000,000USD
    Cash And Short Term Investments———1,528,000,000USD2,957,000,000USD1,993,000,000USD2,078,000,000USD2,627,000,000USD
    Net Debt———15,328,000,000USD15,598,000,000USD15,584,000,000USD15,068,000,000USD16,197,000,000USD
    Short Long Term Debt———23,000,000USD502,000,000USD501,000,000USD505,000,000USD1,200,000,000USD
    Short Long Term Debt Total———16,856,000,000USD18,555,000,000USD17,577,000,000USD17,146,000,000USD18,824,000,000USD
    Property Plant Equipment Gross———10,042,000,000USD9,870,000,000USD9,419,000,000USD9,091,000,000USD9,045,000,000USD
    Common Stock Shares Outstanding———713,700,000shares719,100,000shares720,800,000shares737,200,000shares729,400,000shares
    Non Current Assets Total———70,291,000,000USD70,621,000,000USD69,591,000,000USD68,045,000,000USD70,555,000,000USD
    Non Current Liabilities Total———22,502,000,000USD22,486,000,000USD21,614,000,000USD21,194,000,000USD21,971,000,000USD
    Non Current Liabilities Other———5,660,000,000USD5,633,000,000USD5,638,000,000USD214,000,000USD5,647,000,000USD
    Non Currrent Assets Other———2,341,000,000USD1,108,000,000USD1,039,000,000USD1,091,000,000USD783,000,000USD
    Net Working Capital———3,282,000,000USD4,207,000,000USD2,880,000,000USD2,699,000,000USD2,721,000,000USD
    Unclassified Non Current Assets———-1,141,000,000USD-1,108,000,000USD-1,039,000,000USD-1,091,000,000USD-783,000,000USD
    Unclassified Equity———5,723,000,000USD7,646,000,000USD7,530,000,000USD8,555,000,000USD9,295,000,000USD
    Unclassified Current Liabilities————-502,000,000USD-501,000,000USD-505,000,000USD-1,200,000,000USD
    Current Deferred Revenue——————1,299,000,000USD—
    Unclassified Non Current Liabilities——————5,480,000,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets83,464,000,000USD77,542,000,000USD84,488,000,000USD84,350,000,000USD83,184,000,000USD76,161,000,000USD62,081,600,000USD47,832,500,000USD
    Total Current Assets12,756,000,000USD9,497,000,000USD13,937,000,000USD15,883,000,000USD11,648,000,000USD13,802,000,000USD25,596,600,000USD7,093,800,000USD
    Other Current Assets1,739,000,000USD699,000,000USD842,000,000USD2,059,000,000USD852,000,000USD665,000,000USD787,600,000USD1,562,800,000USD
    Other Non Current Assets4,209,000,000USD———————
    Total Liabilities30,923,000,000USD———————
    Total Current Liabilities6,807,000,000USD6,798,000,000USD8,274,000,000USD8,389,000,000USD8,140,000,000USD7,402,000,000USD4,932,100,000USD4,841,500,000USD
    Other Current Liabilities4,961,000,000USD———————
    Other Non Current Liabilities5,700,000,000USD———————
    Total Stockholder Equity52,534,000,000USD49,543,000,000USD53,486,000,000USD50,082,000,000USD45,167,000,000USD39,766,000,000USD30,270,600,000USD28,214,400,000USD
    Total Equity Including Noncontrolling Interest52,541,000,000USD———————
    Long Term Debt18,416,000,000USD15,500,000,000USD16,707,000,000USD19,086,000,000USD22,168,000,000USD21,193,000,000USD21,516,700,000USD9,688,500,000USD
    Deferred Revenue1,353,000,000USD———————
    Deferred Revenue Non Current231,000,000USD———————
    Net Receivables3,913,000,000USD4,390,000,000USD4,637,000,000USD5,064,000,000USD5,443,000,000USD4,810,000,000USD3,268,400,000USD3,111,800,000USD
    Inventory2,489,000,000USD2,330,000,000USD2,594,000,000USD2,765,000,000USD2,767,000,000USD2,292,000,000USD1,628,300,000USD1,631,400,000USD
    Property Plant Equipment Net6,745,000,000USD6,074,000,000USD5,605,000,000USD4,593,000,000USD4,831,000,000USD4,204,000,000USD3,065,700,000USD2,249,600,000USD
    Goodwill43,151,000,000USD———————
    Intangible Assets17,817,000,000USD18,568,000,000USD20,746,000,000USD19,821,000,000USD22,843,000,000USD21,282,000,000USD9,749,700,000USD10,282,800,000USD
    Accounts Payable1,844,000,000USD1,753,000,000USD1,766,000,000USD1,856,000,000USD2,569,000,000USD2,049,000,000USD1,514,400,000USD1,495,400,000USD
    Short Term Debt2,000,000USD678,000,000USD1,875,000,000USD758,000,000USD215,000,000USD200,000,000USD370,200,000USD51,800,000USD
    Common Stock9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD9,000,000USD8,400,000USD8,200,000USD
    Retained Earnings46,891,000,000USD44,188,000,000USD41,074,000,000USD39,205,000,000USD32,827,000,000USD27,159,000,000USD24,166,300,000USD25,163,000,000USD
    Accumulated Other Comprehensive Income-207,000,000USD-3,218,000,000USD-1,748,000,000USD-2,872,000,000USD-1,027,000,000USD-368,000,000USD-3,068,300,000USD-2,791,100,000USD
    Total Liab—27,992,000,000USD30,998,000,000USD34,260,000,000USD38,007,000,000USD36,384,000,000USD31,799,700,000USD19,605,800,000USD
    Other Current Liab—3,068,000,000USD2,586,000,000USD3,628,000,000USD3,036,000,000USD3,389,000,000USD2,003,200,000USD2,375,100,000USD
    Capital Stock—9,000,000USD9,000,000USD1,677,000,000USD3,277,000,000USD3,277,000,000USD1,608,000,000USD8,200,000USD
    Good Will—40,497,000,000USD41,608,000,000USD37,276,000,000USD41,184,000,000USD35,420,000,000USD22,712,500,000USD22,580,500,000USD
    Other Assets—2,906,000,000USD2,592,000,000USD4,459,000,000USD3,719,000,000USD2,395,000,000USD923,400,000USD5,587,500,000USD
    Cash—2,078,000,000USD5,864,000,000USD5,995,000,000USD2,586,000,000USD6,035,000,000USD19,912,300,000USD787,800,000USD
    Cash And Equivalents—2,078,000,000USD5,864,000,000USD5,995,000,000USD2,586,000,000USD6,035,000,000USD19,912,300,000USD787,800,000USD
    Cash And Short Term Investments—2,078,000,000USD5,864,000,000USD5,995,000,000USD2,586,000,000USD6,035,000,000USD19,912,300,000USD787,800,000USD
    Current Deferred Revenue—1,299,000,000USD1,465,000,000USD1,456,000,000USD1,613,000,000USD1,212,000,000USD687,800,000USD626,800,000USD
    Net Debt—15,068,000,000USD13,672,000,000USD14,621,000,000USD20,686,000,000USD16,143,000,000USD2,613,700,000USD8,952,500,000USD
    Short Long Term Debt—505,000,000USD1,695,000,000USD591,000,000USD8,000,000USD11,000,000USD212,400,000USD51,800,000USD
    Short Long Term Debt Total—17,146,000,000USD19,536,000,000USD20,616,000,000USD23,272,000,000USD22,178,000,000USD22,526,000,000USD9,740,300,000USD
    Property Plant Equipment Gross—9,091,000,000USD8,379,000,000USD7,849,000,000USD7,255,000,000USD3,262,000,000USD2,302,000,000USD2,511,200,000USD
    Common Stock Shares Outstanding—737,200,000shares743,100,000shares737,100,000shares736,800,000shares718,700,000shares725,500,000shares710,200,000shares
    Non Current Assets Total—68,045,000,000USD70,551,000,000USD68,467,000,000USD71,536,000,000USD62,359,000,000USD36,485,000,000USD40,738,700,000USD
    Non Current Liabilities Total—21,194,000,000USD22,724,000,000USD25,871,000,000USD29,867,000,000USD28,982,000,000USD26,867,600,000USD14,764,300,000USD
    Non Current Liabilities Other—214,000,000USD228,000,000USD6,785,000,000USD7,699,000,000USD7,789,000,000USD5,350,900,000USD5,075,800,000USD
    Non Currrent Assets Other—1,091,000,000USD896,000,000USD4,613,000,000USD1,358,000,000USD1,426,000,000USD923,400,000USD5,587,499,999USD
    Net Working Capital—2,699,000,000USD5,663,000,000USD7,494,000,000USD3,508,000,000USD6,400,000,000USD20,664,500,000USD2,252,300,000USD
    Unclassified Non Current Assets—-1,091,000,000USD-896,000,000USD-2,295,000,000USD-2,399,000,000USD-2,368,000,000USD-923,400,000USD-5,587,499,999USD
    Unclassified Current Liabilities—-505,000,000USD-1,113,000,000USD100,000,000USD699,000,000USD541,000,000USD144,100,000USD240,600,000USD
    Unclassified Non Current Liabilities—5,480,000,000USD5,789,000,000USD-5,922,000,000USD-7,699,000,000USD-7,789,000,000USD-4,711,800,000USD-5,075,800,000USD
    Unclassified Equity—8,555,000,000USD14,142,000,000USD12,063,000,000USD10,081,000,000USD9,689,000,000USD7,556,200,000USD5,826,100,000USD
    Other Liab———5,922,000,000USD7,699,000,000USD7,789,000,000USD4,711,800,000USD5,075,800,000USD
    Net Tangible Assets———-11,638,000,000USD-22,128,000,000USD-20,204,000,000USD-3,791,200,000USD-9,364,700,000USD
    Long Term Investments——————33,700,000USD38,300,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-26 · USD
    Net Income1,899,000,000USD
    Depreciation1,286,000,000USD
    Stock Based Compensation151,000,000USD
    Other Non Cash Items130,000,000USD
    Change To Account Receivables137,000,000USD
    Change To Inventory-178,000,000USD
    Change To Liabilities-650,000,000USD
    Change In Working Capital-610,000,000USD
    Operating Cash Flow2,856,000,000USD
    Capital Expenditures-506,000,000USD
    Net Investments-67,000,000USD
    Other Investing Activities-9,843,000,000USD
    Unclassified Investing Cash Flow20,000,000USD
    Investing Cash Flow-10,396,000,000USD
    Net Debt Issuance8,794,000,000USD
    Net Common Stock Issuance-895,000,000USD
    Common Dividends Paid-509,000,000USD
    Other Financing Activities-71,000,000USD
    Financing Cash Flow7,319,000,000USD
    Effect Of Forex Changes On Cash-46,000,000USD
    Change In Cash-267,000,000USD
    End Cash Flow4,348,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-27 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation627,000,000USD522,000,000USD622,000,000USD611,000,000USD591,000,000USD595,000,000USD591,000,000USD580,000,000USD
    Stock Based Compensation58,000,000USD146,000,000USD83,000,000USD91,000,000USD61,000,000USD57,000,000USD84,000,000USD87,000,000USD
    Change To Account Receivables66,000,000USD-151,000,000USD-199,000,000USD45,000,000USD89,000,000USD-151,000,000USD-108,000,000USD74,000,000USD
    Change To Inventory-132,000,000USD184,000,000USD6,000,000USD-82,000,000USD-166,000,000USD264,000,000USD35,000,000USD-34,000,000USD
    Change To Liabilities-41,000,000USD———————
    Change In Working Capital-147,000,000USD155,000,000USD-67,000,000USD-395,000,000USD-403,000,000USD174,000,000USD-99,000,000USD-216,000,000USD
    Operating Cash Flow1,322,000,000USD———————
    Capital Expenditures-237,000,000USD-371,000,000USD-292,000,000USD-248,000,000USD-245,000,000USD-516,000,000USD-298,000,000USD-287,000,000USD
    Net Investments-20,000,000USD———————
    Other Investing Activities-8,000,000USD———————
    Unclassified Investing Cash Flow16,000,000USD201,000,000USD285,000,000USD235,000,000USD238,000,000USD520,000,000USD285,000,000USD275,000,000USD
    Investing Cash Flow-249,000,000USD———————
    Net Debt Issuance1,743,000,000USD———————
    Net Common Stock Issuance0USD———————
    Common Dividends Paid-226,000,000USD———————
    Other Financing Activities-28,000,000USD———————
    Unclassified Financing Cash Flow-1,443,000,000USD-2,041,000,000USD977,000,000USD1,083,000,000USD—162,000,000USD67,000,000USD-950,000,000USD
    Financing Cash Flow46,000,000USD———————
    Effect Of Forex Changes On Cash-33,000,000USD———————
    Change In Cash1,086,000,000USD3,097,000,000USD-782,000,000USD964,000,000USD-85,000,000USD-549,000,000USD253,000,000USD-4,657,000,000USD
    End Cash Flow5,701,000,000USD———————
    Net Income—1,197,000,000USD908,000,000USD555,000,000USD954,000,000USD1,086,000,000USD818,000,000USD907,000,000USD
    Other Non Cash Items—537,000,000USD116,000,000USD476,000,000USD96,000,000USD107,000,000USD119,000,000USD59,000,000USD
    Total Cash From Operating Activities—2,117,000,000USD1,662,000,000USD1,338,000,000USD1,299,000,000USD2,019,000,000USD1,513,000,000USD1,417,000,000USD
    Free Cash Flow—1,746,000,000USD1,370,000,000USD1,090,000,000USD1,054,000,000USD1,503,000,000USD1,215,000,000USD1,130,000,000USD
    Investments—-48,000,000USD-312,000,000USD-258,000,000USD-242,000,000USD-694,000,000USD-606,000,000USD-360,000,000USD
    Total Cashflows From Investing Activities—-384,000,000USD-312,000,000USD-258,000,000USD-242,000,000USD-694,000,000USD-606,000,000USD-360,000,000USD
    Net Borrowings—1,519,000,000USD-477,000,000USD2,000,000USD1,000,000USD-696,000,000USD-14,000,000USD—
    Total Cash From Financing Activities—1,265,000,000USD-2,724,000,000USD-247,000,000USD-1,255,000,000USD-1,692,000,000USD-845,000,000USD-5,715,000,000USD
    Dividends Paid—-226,000,000USD-229,000,000USD-229,000,000USD-194,000,000USD-195,000,000USD-196,000,000USD-200,000,000USD
    Sale Purchase Of Stock—-25,000,000USD-1,985,000,000USD-1,064,000,000USD-1,078,000,000USD-809,000,000USD-640,000,000USD-4,530,000,000USD
    Begin Period Cash Flow—1,518,000,000USD2,300,000,000USD1,993,000,000USD2,078,000,000USD2,627,000,000USD2,374,000,000USD7,031,000,000USD
    End Period Cash Flow—4,615,000,000USD1,518,000,000USD2,957,000,000USD1,993,000,000USD2,078,000,000USD2,627,000,000USD2,374,000,000USD
    Other Cashflows From Investing Activities—-166,000,000USD7,000,000USD13,000,000USD7,000,000USD-4,000,000USD13,000,000USD12,000,000USD
    Other Cashflows From Financing Activities—2,038,000,000USD-1,010,000,000USD-39,000,000USD21,000,000USD-154,000,000USD-62,000,000USD-35,000,000USD
    Unclassified Operating Cash Flow—-440,000,000USD——————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20222022-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20152015-12-31 · USD
    Depreciation2,450,000,000USD2,352,000,000USD2,222,000,000USD1,775,000,000USD1,189,500,000USD1,307,700,000USD1,238,300,000USD1,051,300,000USD
    Stock Based Compensation298,000,000USD288,000,000USD336,000,000USD187,000,000USD158,800,000USD151,400,000USD139,400,000USD139,000,000USD
    Change To Account Receivables-216,000,000USD331,000,000USD-477,000,000USD-264,000,000USD-156,400,000USD-58,300,000USD-161,400,000USD-52,100,000USD
    Change To Inventory-58,000,000USD147,000,000USD-486,000,000USD-123,000,000USD-21,900,000USD-143,300,000USD-27,400,000USD119,700,000USD
    Change To Liabilities9,000,000USD—81,000,000USD372,000,000USD422,600,000USD216,900,000USD258,300,000USD221,800,000USD
    Change In Working Capital-320,000,000USD266,000,000USD-1,519,000,000USD605,000,000USD-123,200,000USD-90,100,000USD-353,000,000USD51,400,000USD
    Operating Cash Flow6,416,000,000USD———————
    Capital Expenditures-1,156,000,000USD-1,392,000,000USD-1,152,000,000USD-791,000,000USD-635,500,000USD-584,000,000USD-570,700,000USD-512,900,000USD
    Net Investments-115,000,000USD———————
    Other Investing Activities-33,000,000USD———————
    Unclassified Investing Cash Flow108,000,000USD1,345,000,000USD2,234,000,000USD——-2,173,300,000USD-138,000,000USD-14,262,000,000USD
    Investing Cash Flow-1,196,000,000USD———————
    Net Debt Issuance-11,000,000USD———————
    Common Stock Issuance85,000,000USD———————
    Net Common Stock Issuance-3,157,000,000USD———————
    Common Dividends Paid-878,000,000USD———————
    Other Financing Activities-125,000,000USD———————
    Unclassified Financing Cash Flow1,125,000,000USD162,000,000USD754,000,000USD-2,154,000,000USD-12,697,900,000USD-315,700,000USD-530,800,000USD462,500,000USD
    Financing Cash Flow-2,961,000,000USD———————
    Effect Of Forex Changes On Cash278,000,000USD———————
    Change In Cash2,537,000,000USD-3,786,000,000USD3,409,000,000USD-13,877,000,000USD19,124,500,000USD157,700,000USD-333,400,000USD-2,214,800,000USD
    End Cash Flow4,615,000,000USD———————
    Net Income—3,899,000,000USD7,209,000,000USD3,646,000,000USD2,432,300,000USD2,650,900,000USD2,469,800,000USD2,598,700,000USD
    Other Non Cash Items—-117,000,000USD830,000,000USD457,000,000USD709,400,000USD197,200,000USD410,200,000USD112,700,000USD
    Total Cash From Operating Activities—6,688,000,000USD8,519,000,000USD6,208,000,000USD3,951,600,000USD4,022,000,000USD3,477,800,000USD3,801,800,000USD
    Free Cash Flow—5,296,000,000USD7,367,000,000USD5,417,000,000USD3,316,100,000USD3,438,000,000USD2,907,100,000USD3,288,900,000USD
    Investments—-1,981,000,000USD-2,234,000,000USD-329,000,000USD-241,000,000USD-126,700,000USD138,000,000USD-87,100,000USD
    Total Cashflows From Investing Activities—-1,981,000,000USD-2,234,000,000USD-21,239,000,000USD-1,238,100,000USD-2,949,000,000USD-843,400,000USD-14,951,000,000USD
    Net Borrowings—-1,669,000,000USD-1,688,000,000USD-1,926,000,000USD13,343,600,000USD-442,100,000USD-2,664,800,000USD9,158,600,000USD
    Total Cash From Financing Activities—-8,385,000,000USD-2,570,000,000USD1,006,000,000USD16,365,900,000USD-797,000,000USD-3,098,500,000USD9,050,200,000USD
    Dividends Paid—-768,000,000USD-818,000,000USD-615,000,000USD-750,700,000USD-433,400,000USD-378,300,000USD-354,100,000USD
    Sale Purchase Of Stock—-5,979,000,000USD934,000,000USD5,704,000,000USD16,514,200,000USD411,800,000USD599,600,000USD-213,500,000USD
    Issuance Of Capital Stock—162,000,000USD31,000,000USD3,550,000,000USD3,816,300,000USD96,000,000USD——
    Begin Period Cash Flow—5,864,000,000USD2,586,000,000USD19,912,000,000USD787,800,000USD630,300,000USD963,700,000USD3,005,600,000USD
    End Period Cash Flow—2,078,000,000USD5,995,000,000USD6,035,000,000USD19,912,300,000USD788,000,000USD630,300,000USD790,800,000USD
    Other Cashflows From Investing Activities—47,000,000USD-1,082,000,000USD-20,119,000,000USD-361,600,000USD-65,000,000USD-272,700,000USD-89,000,000USD
    Other Cashflows From Financing Activities—-131,000,000USD-1,752,000,000USD-3,000,000USD-43,300,000USD-17,600,000USD-124,200,000USD-3,300,000USD
    Cash And Cash Equivalents Changes——3,715,000,000USD-14,025,000,000USD19,124,500,000USD157,500,000USD-333,400,000USD-2,214,800,000USD
    Unclassified Operating Cash Flow——-559,000,000USD-462,000,000USD-415,200,000USD-195,100,000USD-426,900,000USD-151,300,000USD
    Exchange Rate Changes————45,100,000USD-117,700,000USD130,700,000USD-115,800,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Biotechnology Price Contribution to Sales Growth

    Period endPeriodValueUnitSource
    2026-06-26quarterly1.5percentage pointsDisclosure

    Consolidated Price Contribution to Sales Growth

    Period endPeriodValueUnitSource
    2026-06-26quarterly-0.5percentage pointsDisclosure

    Diagnostics Price Contribution to Sales Growth

    Period endPeriodValueUnitSource
    2026-06-26quarterly-1.5percentage pointsDisclosure

    Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-26instant7,500,000,000USDDisclosure

    Respiratory Testing Sales

    Period endPeriodValueUnitSource
    2026-06-26quarterly250USD millionDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-27GeographyHigh Growth Markets1,624,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27GeographyNorth America2,478,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27GeographyOther Developed Markets284,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27GeographyWestern Europe1,565,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27ProductRevenuefrom Contractwith Customer Measurement Nonrecurring920,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27ProductRevenuefrom Contractwith Customer Measurement Recurring5,031,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27SegmentBiotechnology1,797,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27SegmentDiagnostics2,417,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-27SegmentLife Sciences1,737,000,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,514,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring5,324,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring4,441,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring20,127,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentBiotechnology7,293,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentDiagnostics9,941,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentLife Sciences7,334,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyHigh Growth Markets1,761,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyNorth America2,580,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyOther Developed Markets316,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyWestern Europe1,396,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,036,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductRevenuefrom Contractwith Customer Measurement Recurring5,017,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentBiotechnology1,798,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentDiagnostics2,463,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentLife Sciences1,792,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyHigh Growth Markets1,697,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyNorth America2,438,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyOther Developed Markets294,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyWestern Europe1,507,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductRevenuefrom Contractwith Customer Measurement Nonrecurring966,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductRevenuefrom Contractwith Customer Measurement Recurring4,970,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentBiotechnology1,850,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentDiagnostics2,309,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentLife Sciences1,777,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,433,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring5,105,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentBiotechnology1,869,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentDiagnostics2,637,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentLife Sciences2,032,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring4,509,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring19,366,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentBiotechnology6,759,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentDiagnostics9,787,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentLife Sciences7,329,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyHigh Growth Markets1,723,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyNorth America2,456,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyOther Developed Markets299,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyWestern Europe1,320,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,021,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductRevenuefrom Contractwith Customer Measurement Recurring4,777,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentBiotechnology1,653,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentDiagnostics2,363,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentLife Sciences1,782,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyHigh Growth Markets1,696,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyNorth America2,434,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyOther Developed Markets292,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyWestern Europe1,321,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,054,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductRevenuefrom Contractwith Customer Measurement Recurring4,689,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentBiotechnology1,713,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentDiagnostics2,260,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentLife Sciences1,770,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyHigh Growth Markets1,537,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyNorth America2,632,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyOther Developed Markets303,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyWestern Europe1,324,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring1,001,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductRevenuefrom Contractwith Customer Measurement Recurring4,795,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31SegmentBiotechnology1,524,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31SegmentDiagnostics2,527,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31SegmentLife Sciences1,745,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring5,208,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring18,682,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentBiotechnology7,172,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentDiagnostics9,577,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentLife Sciences7,141,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyHighgrowthmarkets1,751,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyNorth America2,375,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyOtherdevelopedmarkets300,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyWestern Europe1,198,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30SegmentBiotechnology1,664,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30SegmentDiagnostics2,254,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30SegmentLife Sciences1,706,000,000USDDisclosure
    Q2 2023Quarterly · 2023-06-30GeographyHighgrowthmarkets1,842,000,000USD0000313616-24-000186
    Q2 2023Quarterly · 2023-06-30GeographyNorth America2,350,000,000USD0000313616-24-000186
    Q2 2023Quarterly · 2023-06-30GeographyOtherdevelopedmarkets296,000,000USD0000313616-24-000186
    Q2 2023Quarterly · 2023-06-30GeographyWestern Europe1,424,000,000USD0000313616-24-000186
    FY 2022Yearly · 2022-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring5,767,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring20,876,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentBiotechnology8,758,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentDiagnostics10,849,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentLife Sciences7,036,000,000USDDisclosure
    FY 2021Yearly · 2021-12-31ProductRevenuefrom Contractwith Customer Measurement Nonrecurring5,667,000,000USD0000313616-24-000052
    FY 2021Yearly · 2021-12-31ProductRevenuefrom Contractwith Customer Measurement Recurring19,135,000,000USD0000313616-24-000052
    FY 2021Yearly · 2021-12-31SegmentBiotechnology8,570,000,000USD0000313616-24-000052
    FY 2021Yearly · 2021-12-31SegmentDiagnostics9,844,000,000USD0000313616-24-000052
    FY 2021Yearly · 2021-12-31SegmentLife Sciences6,388,000,000USD0000313616-24-000052
    FY 2020Yearly · 2020-12-31SegmentBiotechnology5,276,000,000USD0000313616-23-000087
    FY 2020Yearly · 2020-12-31SegmentDiagnostics7,403,000,000USD0000313616-23-000087
    FY 2020Yearly · 2020-12-31SegmentEnvironmental Applied Solutions4,305,000,000USD0000313616-23-000087

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.